At a glance
| Alternate name | Examorelin |
|---|---|
| Peptide length | 6 amino acids |
| Endocrine target | Ghrelin / GH-secretagogue receptor |
| Experimental cardiac target | CD36 |
| US approval | No approved medicine |
Overview
Hexarelin was developed within the synthetic growth hormone-secretagogue family and is also called examorelin. Its research history includes short endocrine experiments in healthy volunteers and laboratory investigations of cardiac tissue. Some popular descriptions call it cardioprotective, but this compresses a diverse preclinical literature into a claim not established by clinical outcome trials. The distinction between GH-mediated effects and direct cardiac binding is important. There is no FDA-approved hexarelin product or routine therapeutic indication. Its potency as a hormone stimulus should not be interpreted as evidence that stronger stimulation provides better recovery, better muscle function, or lower cardiovascular risk.
How it works
Hexarelin activates the ghrelin-receptor pathway to stimulate GH release and can interact with endogenous GHRH signaling. Experimental work also identified binding to CD36 in cardiac tissue, a separate receptor-related mechanism. These pathways are not synonymous: a pituitary GH response does not predict the direction of every cardiac effect. Studies in isolated hearts reported altered coronary perfusion pressure, underscoring that the cardiovascular pharmacology is complex.
Human hormone-response experiments
A small study in healthy men found that hexarelin stimulated GH and interacted with GHRH and somatostatin. The investigators were examining regulation of secretion, not clinical strength or cardiovascular endpoints. Such studies establish pharmacology but provide little information about repeated long-term exposure in older adults or patients with chronic disease.
Supporting sources [1]
Why the cardiac claims require caution
A primary animal study identified CD36 as a binding target and showed increased coronary perfusion pressure after hexarelin in isolated hearts. The response differed in models lacking CD36. This is mechanistic evidence, not a human heart-failure trial, and it should not be simplified into a universal beneficial cardiovascular effect.
Supporting sources [2]
What is not established
The cited studies cannot define long-term metabolic, cardiovascular, reproductive, or cancer-related risk in humans. Research-grade product identity and sterility add separate uncertainty if material is used outside a controlled program. The absence of an established adverse-event rate reflects limited clinical exposure, not a measured finding that serious harms are absent.
Is a more potent secretagogue necessarily better?
No. A larger GH response is an experimental measurement, not a patient-centered outcome. A useful treatment must improve a clinically meaningful endpoint with an acceptable safety balance. Hexarelin has no FDA-approved indication for anti-aging, bodybuilding, injury recovery, or cardiovascular prevention, and related-peptide studies do not supply that missing evidence.
Reading this profile
Jurisdiction: United States: investigational molecule with no FDA-approved therapeutic indication.. Molecular class: Synthetic hexapeptide growth hormone secretagogue.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Modulation of growth hormone-releasing activity of hexarelin in man. ↗Original research · Checked 2026-10-27
- CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. ↗Original research · Checked 2026-10-27